CoChat

Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

PURPOSE: To study the progression of retinal pigment epithelium (RPE) and choroidal atrophy in patients with neovascular age-related macular degeneration (AMD) and to assess for a possible association with the number and type of anti-vascular endothelial growth factor treatments. METHODS: Patients with neovascular AMD and a minimum of 1-year follow-up were reviewed. Fellow eyes with nonneovascular AMD were used as control eyes. Retinal pigment epithelial atrophy area and choroidal thickness were determined using spectral-domain optical coherence tomography. Multivariable regression models were used for statistical analyses. RESULTS: A total of 415 eyes were included in the study, with a mean follow-up of 2.2 years. Eyes with neovascular AMD had greater progression of RPE atrophy and choroidal atrophy compared with those with nonneovascular AMD (P < 0.001). Progression of RPE atrophy and choroidal atrophy was independently associated with the total number of injections of bevacizumab and ranibizumab (all P values ≤ 0.001). In the subgroup of 84 eyes with neovascular AMD and without RPE atrophy at baseline, only bevacizumab was associated with the progression of RPE atrophy (P = 0.003). This study likely lacked statistical power to detect an association with ranibizumab in this subgroup. CONCLUSION: Retinal pigment epithelial atrophy and choroidal atrophy in neovascular AMD seem to be exacerbated by anti-vascular endothelial growth factor treatment. Possible differences between bevacizumab and ranibizumab require further investigation.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000000081

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Cited by

See all 78

Metadata

Authors
Young, M., Chui, L., Fallah, N., Or, C., Merkur, A. B., Kirker, A. W., Albiani, D. A., & Forooghian, F.
Affiliations
  • Praxis Spinal Cord Institute (CA)
  • University of British Columbia (CA)
Corresponding author
  • Young, Mei
  • Chui, Lica
  • Or, Chris
  • Merkur, Andrew B.
  • Kirker, Andrew W.
  • Albiani, David A.
  • Forooghian, Farzin
Venue
Retina
Published
2014-07
Volume
34
Issue
7
Pages
1308-1315
ISSN
0275-004X (ISSN-L)
OpenAlex
W1979285901
Cited by
78
References
4
Citations by year
2025: 3 · 2024: 2 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 4 · 2019: 3 · 2018: 10 · 2017: 6 · 2016: 16 · 2015: 5 · 2014: 5
FWCI
9.96
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
neovascular age-related macular degeneration, retinal pigment epithelium atrophy, choroidal atrophy, anti-VEGF therapy, bevacizumab, ranibizumab, treatment side effects, choroidal thickness, disease progression
MeSH terms
Bevacizumab, Ranibizumab, Aged, 80 and over, Atrophy, Choroid, Female, Humans, Male, Postoperative Complications, Retrospective Studies, Disease Progression, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Retinal Pigment Epithelium, Wet Macular Degeneration, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1097/iae.0000000000000081
The paper
Young, M., Chui, L., Fallah, N., Or, C., Merkur, A. B., Kirker, A. W., Albiani, D. A., & Forooghian, F. (2014). Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina. https://doi.org/10.1097/iae.0000000000000081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.